Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?

J&J/Merck is still pursuing an Rx-to-OTC switch of a 20 mg dose of the cholesterol-lowering therapy Mevacor (lovastatin), according to VP-Global Regulatory & Scientific Affairs Edwin Hemwall, PhD